SRC Users' Meeting - Synchrotron Radiation Center - University of ...
SRC Users' Meeting - Synchrotron Radiation Center - University of ... SRC Users' Meeting - Synchrotron Radiation Center - University of ...
SUBCELLULAR DISTRIBUTION OF MOTEXAFIN GADOLINIUM IN TUMOR CELLS M. J. Daniels 1 , R. J. Erhardt 1 , B. H. Frazer 1 , D. Rajesh 2 , S. P. Howard 2 , M. P. Mehta 2 , G. De Stasio 1 1 UW-Madison-SRC, 3731 Schneider Dr., Stoughton WI, 53589 2 Department of Human Oncology, Medical School UW-Madison, Madison WI 53792 Gadolinium Neutron Capture Therapy (GdNCT) is a brain cancer therapy at the experimental stages. It requires that Gd target the nuclei of cancer cells, while sparing those of healthy tissue. In our multi-year quest for the optimum Gd compound to use for this therapy, we recently tested Motexafin gadolinium (MGd). MGd is an agent with known tumor specificity, as revealed by MRI, proposed as a radiosensitizer. Macroscopic tumor uptake of MGd has been well documented, but the microscopic, subcellular distribution of MGd is not well known. We studied the subcellular distribution of MGd in two different in vitro cell lines, TB10 and U87 (both human glioblastoma cells) using the Spectromicroscope for PHotoelectron Imaging of Nanostructures with X-rays (SPHINX) at SRC. Our extensive data analysis revealed that 86% of the cell nuclei contained Gd. This result is promising because we previously calculated that an effective GdNCT agent must target >90% of cell nuclei. Furthermore, this studied showed that the concentration of Gd was highest in the cytoplasm, than the nucleus, but with longer exposure times this nuclear Gd concentration seemed to increase.
X-RAY PHOTOELECTRON EMISSION SPECTROMICROSCOPY REVEALS THAT POLYSACCHARIDES TEMPLATE ASSEMBLY OF BIOGENIC NANOSCALE CRYSTAL FIBERS G. De Stasio 1 , C.S. Chan 2 , S.A. Welch 3 , M. Girasole 4 , B.H. Frazer 1 , M. Nesterova 5 , L.M. Weise 1 and J.F. Banfield 2 (1) UW-Madison (2) UC-Berkeley (3) Australian National University (4) Italian National Research Council Neutrophilic iron oxidizing bacteria extract metabolic energy from iron oxidation in various environments, such as groundwater seeps, streams, wetlands, the rhizosphere, and hydrothermal vents. Their physiology is not well understood, and in particular the role of extracellular polymers in iron oxide mineralization and possibly energy metabolism. Recent experiments with the Spectromicroscope for PHotoelectron Imaging of Nanostructure with X-rays (SPHINX) on precipitated Fe oxides in biofilms clarified that microbially extruded polysaccharide filaments provide the precipitation substrate for amorphous FeOOH. Upon aging the mineralized filaments crystallize to ferrihydrite (2-line FeOOH), with one curved pseudo-single crystal of akaganeite (-FeOOH), at the core of each filament, of aspect ratio 1:1000:1. Structure and morphology of this unusual and unprecedented nanoscale crystal is therefore templated by polysaccharides. After formation of the crystal fiber, the polysaccharide structure is also altered, and C1s spectra suggest that the COO - group is involved in the templation mechanism.
- Page 2 and 3: Welcome to the 36 th SRC Users’ M
- Page 4 and 5: 12:20 - 1:10 Lunch 1:10 -1:45 Poste
- Page 6 and 7: Administration Executive Director D
- Page 8 and 9: STATUS OF THE SRC BEAMLINES AND INS
- Page 10 and 11: ACCELERATOR DEVELOPMENTS Ken Jacobs
- Page 12 and 13: HIGH ENERGY RESEARCH POSSIBILITIES
- Page 14 and 15: ATOMICALLY UNIFORM THIN FILMS ON SI
- Page 16 and 17: calculated binding energies of the
- Page 18 and 19: MANY-ELECTRON EFFECTS ON THE XE 5S
- Page 20 and 21: PHOTOELECTRON SPECTROMETRY OF ATOMI
- Page 22 and 23: PHOTOEMISSION STUDY OF USb AND UTe
- Page 24 and 25: CANADIAN SYNCHROTRON RADIATION FACI
- Page 26 and 27: SELF-ASSEMBLY OF BLOCK COPOLYMERS O
- Page 28 and 29: A B S T R A C T S
- Page 30 and 31: Photoemission spectra, a.u. -0.3 -0
- Page 32 and 33: THE INITIAL AND FINAL STATE BANDS I
- Page 34 and 35: TRANSITION LAYERS AT BURIED FERROMA
- Page 36 and 37: LOW-DIMENSIONAL ELECTRONS AT SILICO
- Page 40 and 41: LINEAR POLARIZATION MEASUREMENTS OF
- Page 42 and 43: Fig.1: Photoemission spectra of opt
- Page 44 and 45: The sample manipulator has a cool d
- Page 46 and 47: Cr and Fe but for these U systems t
- Page 48 and 49: [4] G. -H. Gweon, J. W. Allen, and
- Page 50 and 51: References [1] S. Cho, Y. Kim, A. D
- Page 52 and 53: [3] D. L. Mills, Physical Review B
- Page 54 and 55: CHARACTERIZATION OF SULPHATE INTERA
- Page 56 and 57: in the data acquisition chamber. Th
- Page 58 and 59: spatially resolved chemistry of the
- Page 60 and 61: THE RELATIONSHIP BETWEEN PHOSPHATE
- Page 62 and 63: PHOTOEMISSION STUDIES OF QUANTUM WE
- Page 64 and 65: Ag surface state such that it moves
- Page 66 and 67: HIGH-RESOLUTION STUDY OF THE LITHIU
- Page 68 and 69: RELATIVE PARTIAL CROSS SECTIONS AND
- Page 70 and 71: Christian Ast Max-Planck Institute
- Page 72 and 73: David L. Huber Physical Sciences La
- Page 74 and 75: Tom Miller University of Illinois a
- Page 76 and 77: Eric Wiedemann University of Wiscon
- Page 78 and 79: Pete Hagen Phone: (608) 877-2154 Em
- Page 80: NOTES
SUBCELLULAR DISTRIBUTION OF<br />
MOTEXAFIN GADOLINIUM IN TUMOR CELLS<br />
M. J. Daniels 1 , R. J. Erhardt 1 , B. H. Frazer 1 , D. Rajesh 2 ,<br />
S. P. Howard 2 , M. P. Mehta 2 , G. De Stasio 1<br />
1 UW-Madison-<strong>SRC</strong>, 3731 Schneider Dr., Stoughton WI, 53589<br />
2 Department <strong>of</strong> Human Oncology, Medical School UW-Madison, Madison WI 53792<br />
Gadolinium Neutron Capture Therapy (GdNCT) is a brain cancer therapy at the<br />
experimental stages. It requires that Gd target the nuclei <strong>of</strong> cancer cells, while sparing those <strong>of</strong><br />
healthy tissue. In our multi-year quest for the optimum Gd compound to use for this therapy, we<br />
recently tested Motexafin gadolinium (MGd). MGd is an agent with known tumor specificity, as<br />
revealed by MRI, proposed as a radiosensitizer. Macroscopic tumor uptake <strong>of</strong> MGd has been<br />
well documented, but the microscopic, subcellular distribution <strong>of</strong> MGd is not well known. We<br />
studied the subcellular distribution <strong>of</strong> MGd in two different in vitro cell lines, TB10 and U87<br />
(both human glioblastoma cells) using the Spectromicroscope for PHotoelectron Imaging <strong>of</strong><br />
Nanostructures with X-rays (SPHINX) at <strong>SRC</strong>. Our extensive data analysis revealed that 86% <strong>of</strong><br />
the cell nuclei contained Gd. This result is promising because we previously calculated that an<br />
effective GdNCT agent must target >90% <strong>of</strong> cell nuclei. Furthermore, this studied showed that<br />
the concentration <strong>of</strong> Gd was highest in the cytoplasm, than the nucleus, but with longer exposure<br />
times this nuclear Gd concentration seemed to increase.
Change language